Ask about Innovation, Learn about Drug Development from a Company Perspective
Post Date: April 11, 2022 | Publish Date:
From concept through preclinical testing in the laboratory, to clinical trial development and execution, the typical journey to an approved vaccine or drug is understandably long and expensive. The strategy of in-licensing technologies from academic institutions is attractive to the biopharma industry because it expedites development and mitigates the investment risk.
For academic researchers who may be unfamiliar with commercialization, an upcoming virtual event has been designed to educate about innovation and partnering with industry.
On Tuesday, Apr. 19, 2022 at 1:30 pm ET, Cincinnati Children’s Innovation Ventures (CCIV) will host a livestream event, titled Ask about Innovation, Learn about Drug Development from a Company Perspective.
Led by CCIV’s Justin Levy, JD, this one-hour virtual conversation with Enrique Lin Shiao, PhD, an asset acquisitions associate with BridgeBio Pharma, will provide more details about how technology is assessed by industry partners and eligibility for funding.
It will also describe the BridgeBio-Cincinnati Children’s Research Alliance, which was formed in 2018 with the goal of advancing novel therapeutics from bench to bedside. BridgeBio Pharma has a team of experienced drug discoverers, developers, and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source.
1:30 pm ET, Tuesday, Apr. 19, 2022
This event will be livestreamed via Zoom and is free and open to the public. There is also limited seating available in-person for Cincinnati Children’s and the University of Cincinnati employees only.
Registration is required, and those who are interested in attending are encouraged to email firstname.lastname@example.org by Monday, Apr. 18 to register.
Cincinnati Children’s investigators are encouraged to visit CenterLink to learn about eligibility for funding and laboratory research support from the BridgeBio Pharma and Cincinnati Children’s Research Alliance.